|
|
Volumn 303, Issue 3, 2010, Pages 211-212
|
|
Cholesterol drug lowers LDL-C levels but again fails to show clinical benefit
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
C REACTIVE PROTEIN;
CALCIUM;
EZETIMIBE;
EZETIMIBE PLUS SIMVASTATIN;
HIGH DENSITY LIPOPROTEIN CHOLESTEROL;
HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;
LOW DENSITY LIPOPROTEIN CHOLESTEROL;
NICOTINIC ACID;
ADD ON THERAPY;
ADJUVANT THERAPY;
ARTERIAL WALL THICKNESS;
ATHEROSCLEROSIS;
CALCIUM BLOOD LEVEL;
CARDIOVASCULAR RISK;
CHOLESTEROL BLOOD LEVEL;
CLINICAL STUDY;
COMPARATIVE STUDY;
CONTROLLED STUDY;
DEATH;
DIABETES MELLITUS;
DISEASE COURSE;
DISEASE MARKER;
DRUG APPROVAL;
DRUG EFFICACY;
DRUG MARKETING;
DRUG RELEASE;
HEART INFARCTION;
HEART PROTECTION;
HUMAN;
HYPERCHOLESTEROLEMIA;
ISCHEMIC HEART DISEASE;
PRESCRIPTION;
PRIORITY JOURNAL;
RISK ASSESSMENT;
RISK BENEFIT ANALYSIS;
SEX DIFFERENCE;
SHORT SURVEY;
STROKE;
TREATMENT DURATION;
|
|
EID: 74549194017
PISSN: 00987484
EISSN: 15383598
Source Type: Journal
DOI: 10.1001/jama.2009.1915 Document Type: Short Survey |
|
Times cited : (4)
|
|
References (0)
|